Scientific Advisory Board

Oligomerix has assembled a multi-disciplined team of thought leaders to provide scientific insight and guidance for its R&D programs for neurodegenerative diseases:

Peter Davies, Ph.D., Professor, Pathology and Neuroscience Director, Litwin-Zucker Center for Research on Alzheimer’s Disease

Peter Davies received a B.Sc. and a Ph.D. from the University of Leeds, England. He was a post-doctoral fellow in the Department of Pharmacology at the University of Edinburgh, Scotland before joining the staff of the Medical Research Council in Edinburgh in 1974, where he began his research on Alzheimer’s disease. In 1977, he moved to Albert Einstein College of Medicine in the Bronx, and became the Scientific Director of the Litwin/Zucker Center for Research on Alzheimer’s disease at the Feinstein Institute for Medical Research, North Shore/LIJ in 2006. Dr Davies research has been focused on biochemistry of Alzheimer’s disease. He has published about 300 papers, and has been interested in the development of new treatments and diagnostic tests for Alzheimer’s disease. He has received numerous awards for his research, including a Lifetime Achievement Award from the International Congress on Alzheimer’s Disease (ICAD), the first Metropolitan Life Foundation Prize and the Potamkin Prize. Dr Davies has received two MERIT awards from the National Institutes of Health.

Steven Jacobsen, Ph.D., Senior Project Director, Neuroscience iMed, AstraZeneca Neurosciences

Dr. Jacobsen joined AstraZeneca, Neuroscience iMed as Senior Project Director in December 2012, from Proteostasis Therapeutics, a drug development startup, where he was Vice President, Head of Translational Biology Department for two years. He has extensive drug development experience in the pharmaceutical industry, with focus on neurodegeneration and the targeting of misfolded proteins, having been Senior Research Fellow, Neuroscience Translation at Pfizer Global R&D, and Associate Director and Team Leader, Alzheime’s disease-Modifying Program at Wyeth Research. Prior to that, Dr.Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid. In addition, he serves on the Scientific Advisory Boards of several biotechnology startup organizations, and is adjunct Associate Professor at New York University School of Medicine.

R.P. “Kris” Iyer, Ph.D., Co-Founder, Chief Scientific Officer, Spring Bank Pharmaceuticals

Kris is an innovator in the fields of nucleic acid chemistry, bioorganic chemistry and pharmaceutical sciences. He was co-founder and VP of Discovery of Origenix Technologies, Inc. from 1998 to 2002. There he directed a team of 30 scientists in chemistry and biology and was instrumental in advancing several programs from discovery to clinical development. From 1993 to 1998, Kris was a Senior Scientist and Associate Director of the Discovery Group at Hybridon, Inc. (now Idera Pharmaceuticals, Inc.). Previously, Kris was a Professor of Medicinal Chemistry at the University of Bombay, a Visiting Scientist at the University of Texas, M.D. Anderson Cancer Center and a Visiting Scientist at the Center for Biologics Evaluation and Research at FDA/NIH. Kris received his BS (Hons) in chemistry, BS and MS degrees in Medicinal and Pharmaceutical Chemistry from the University of Bombay. He received his PhD degree in Pharmaceutical Sciences from the University of the Pacific, Stockton, California and carried out postdoctoral work at the Oak Ridge National Laboratory and at the Johns Hopkins University. He is an author of over 100 scientific papers and several books on organic synthesis and is an inventor of more than 100 patents and patent applications.